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Objectives: There is a need for a brief, reliable, valid, and sensitive assessment tool
for screening cognitive deficits in patients with Major Depressive Disorders. This
paper examines the psychometric characteristics of THINC‐it, a cognitive assessment- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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H. Lundbeck A/S tool composed of four objective measures of cognition and a self‐rated assessment, in
subjects without mental disorders.
Methods: N = 100 healthy controls with no current or past history of depression
were tested on four sequential assessments to examine temporal stability, reliability,
and convergent validity of theTHINC‐it tests. We examined temporal reliability across
1 week and stability via three consecutive assessments. Consistency of assessment by
the study rater (intrarater reliability) was calculated using the data from the second
and third of these consecutive assessments.
Results: Test–retest reliability correlations varied between Pearson's r = 0.75 and
0.8. Intrarater reliability between 0.7 and 0.93. Stability for the primary measure for
each test yielded within‐subject standard deviation values between 5.9 and 11.23 for
accuracy measures and 0.735 and 17.3 seconds for latency measures. Convergent
validity for three tasks was in the acceptable range, but low for the Symbol Check task.
Conclusions: Analysis shows high levels of reliability and stability. Levels of conver-
gent validity were modest but acceptable in the case of all but one test.
KEYWORDS
cognition, depression, memory, neuropsychological, screening1 | INTRODUCTION
Recent research into the cognitive difficulties experienced by patients
with Major Depressive Disorders (MDD) has revealed a reduced
capacity in function equal to an effect size in the region of 0.5 across
various cognitive domains when compared to the performance of
typical controls, even when patients are in remission (e.g., Rock,
Roiser, Riedel, & Blackwell, 2014). These cognitive difficulties have
been shown to be present at the first episode of depression (Lee,
Hermens, Porter, & Redoblado‐Hodge, 2012), and a significant num-
ber of patients continue to experience difficulties between depressive
episodes (Conradi, Ormel, & de Jonge, 2011; Roca et al., 2015).
Clinical research has yielded various candidate measures for
assessing, evaluating, and detecting cognitive difficulties in patients
with MDD (see Harrison, Lam, Baune, & McIntyre, 2016). This litera-
ture has been helpful for identifying the cognitive domains in which
depression associated impairment is observed, as well as the magni-
tude of these effects. This research has also been instrumental to
inform the selection of cognitive assessments appropriate for screen-
ing purposes for cognitive difficulties in patients with MDD.
Routine care screening for cognitive deficits in patients with
depression remains a rare phenomenon, unless other nonmood diag-
noses are contemplated (McAllister‐Williams et al., 2017). This is espe-
cially the case in older patients, in whom dementia might be
suspected. When cognitive performance is assessed, it is typically with
brief, portmanteau tests such as the Mini‐Mental States Examination
and the Montreal Cognitive Assessment (Folstein, Folstein, &
McHugh, 1975; Nasreddine et al., 2005). Both measures have a useful
role to play as brief, bedside tests of global cognitive function, but are
very unlikely to detect the types, forms, and the severity of cognitive
dysfunction seen in MDD. Standardized tests for measuring cognitivedifficulties in patients with MDD would offer health care professionals
a further option for assessment. The demands of contemporary
patient care require that screening measures and tests of change in
the patients' status should be tested using reliable, sensitive, and valid
measures (Harrison, 2016). Other computerized cognitive measures
have been employed to assess the cognitive performance of patients
with MDD. For example, the Cambridge Neuropsychological Test
Automated Battery system has been employed in several studies,
the results of which were recently reported in a meta‐analysis (Rock
et al., 2014). Additionally, both the CogState system (Harrison &
Maruff, 2008) and the assessment from central nervous system vital
signs (Gualtieri & Johnson, 2006) have been employed to investigate
cognitive function in depression. These systems contain computerized
paradigms designed to index key cognitive areas. However, a chal-
lenge to employing one of these proprietary testing platforms is the
task duration. Potential clinical users informed us that a brief assess-
ment was required. Candidate tests of, for example, executive functions,
can be rather lengthy. For example, the Groton Maze Learning Test
requires at least 7 minutes (https://www.cogstate.com/cognitive‐
tests/groton‐maze‐learning/). Cambridge Neuropsychological Test
Automated Battery measures, such as the “One Touch Stockings of
Cambridge” Test, require at least 10 minutes to administer (http://
www.cambridgecognition.com/cantab/cognitive‐tests/executive‐func-
tion/one‐touch‐stockings‐of‐cambridge‐ots/). A further issue mitigating
against the use of these systems was our need to provide tests for free.
Recently, we have developed and field‐tested a novel screening
tool for health care professionals called THINC‐it that assesses key
domains of function known to be compromised in patients with
MDD. THINC‐it is a digital, gamified cognitive assessment tool devel-
oped by theTHINC Task Force (http://thinc.progress.im), composed of
experts in psychology, psychiatry, primary care, psychometrics,
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via computers/tablets and is composed of well‐known cognitive para-
digms. The selected paradigms were chosen on the basis of their prior
use with patients with MDD and their brevity. A further selection prin-
cipal was to employ paradigms that are acknowledged to index perfor-
mance in the key cognitive areas of working memory, attention, and
executive function. The “One‐Back” paradigm (Kirchner, 1958) was
selected as a measure of working memory (“Symbol Check”); Choice
ReactionTime (Donders, 1969) as the measure of attention (“Spotter”),
and Part B of theTrail MakingTest (Strauss, Sherman, & Spreen, 2006)
as a measure of executive function (“Trails”). In addition to these par-
adigms, it was also decided to include a computerized variant
(“Codebreaker”) of the Digit Symbol SubstitutionTest (DSST) paradigm
(Lezak, 1995). Competent DSST performance is considered dependent
on the functional integrity of various cognitive skills, including working
memory, attention, and executive function (Harrison, Lophaven, &
Olsen, 2016). In addition to these four objective measures of cogni-
tion, THINC‐it also includes the Perceived Deficits Questionnaire—
Depression, 5‐item (PDQ‐5‐D) as a subjective measure of cognitive
function. This measure asks the patient to rate his/her performance
regarding attention/concentration, planning/organization, and retro-
spective and prospective memory (Lam et al., 2013; Lovera et al.,
2006). Each of theTHINC‐it assessments have been employed in stud-
ies involving adults with MDD and evaluate domains of cognitive
function affected in MDD (McIntyre et al., 2017) Validation reports
of the individual objective measures of cognition contained within
THINC‐it are published elsewhere. These tests have been shown to
be sensitive to cognitive deficits in MDD and are independent of cul-
tural background (McIntyre et al., 2017).
Recently, we reported initial evidence of THINC‐it feasibility,
“caseness” and the ability to differentiate MDD patients from healthy
controls (McIntyre et al., 2017). In this present report, we examine
1. the temporal reliability of the THINC‐it tests across a one‐week
period;
2. the within‐subject variance of THINC‐it test performance as a
measure of test stability;
3. the correlation of the THINC‐it paradigms measures with ana-
logues of the selected tasks; and
4. the intrarater reliability of the measures.2 | METHODS
2.1 | Design
This analysis was part of a larger and more comprehensive project in
which the cognitive performance of patients with MDD was assessed
using a complex study and testing protocol (McIntyre et al., 2017). The
study design and a summary of visits and assessments is shown in
Figure 1. Full details of the trial are reported at https://clinicaltrials.
gov/ct2/show/NCT02508493. Briefly, the first study visit was
planned to allow for correlations between THINC‐it and comparison
tests to determine levels of concurrent validity. Calculations ofwithin‐subject standard deviation (WSD) across all four THINC‐it
assessments at Visit 1 allowed for estimates of test stability to be
made. Correlations between Visit 1 Assessments 2 and 3 were
designed to determine the levels of intrarater reliability. Study Visit 2
was incorporated to evaluate estimates of temporal reliability which
were determined by correlating performance.2.2 | Study participants
The N = 100 subjects were recruited via social media. They responded
to media announcements seeking healthy controls who wished to par-
ticipate in a study evaluating cognitive function. The media website
was www.kijiji.com. All subjects were carefully screened and examined
for current and past mental disorder by the Mini International Neuro-
psychiatric Interview for Diagnostic and Statistical Manual of Mental
Disorders (Sheehan et al., 2006). Healthy subjects were included if
they had no current nor a past mental disorder, no first‐degree relative
with an established diagnosis of a lifetime mood or psychiatric disor-
der. Exclusion criteria were (a) unstable medical disorder(s) (b) any
medication that, in the opinion of the investigator, may have affected
cognitive function (e.g., corticosteroids and beta‐blockers); and (c) con-
sumption of alcohol within 8 hr prior to the THINC‐it tool administra-
tion. Participants received financial compensation for their
participation of 50.00 CAD per visit.2.3 | Assessments
The assessment instruments featured the iPad version of theTHINC‐it
tool (i.e., Spotter, Symbol Check, Codebreaker, Trails, and PDQ‐5‐D);
the Identification Task and One‐Back Memory (OBK) task from the
CogState battery, as well as the pencil‐and‐paper versions of the
DSST, Trail Making Test Part B (TMT‐B) and PDQ‐5‐D. The National
Adult Reading Test—Revised was also included as an estimate
premorbid IQ (Nelson, 1982). For each THINC‐it test, a primary mea-
sure was selected for analysis. We selected the measures analogous
to those most typically chosen for the CogState and paper‐and‐pencil
measures. These measures are reported in Table 1. THINC‐it takes
approximately 15 min to administer with instructions commensurate
with minimal education for administration (i.e., Grade 6).2.4 | Procedures
The order of administration between the THINC‐it tool and the com-
parison tests (the two CogState tasks and pencil‐and‐paper test ver-
sions) was alternated between study participants to account for
potential order effects. The sequence of theTHINC‐it tool component
scales remained identical for all study participants and was adminis-
tered in the following order: Spotter, Symbol Check, Codebreaker,
Trails, and PDQ‐5‐D. The comparison tests were administered in the
following order: Identification Task, OBK, DSST, TMT‐B, and PDQ‐5‐
D. All participants completed the full set of cognitive assessments
(i.e., THINC‐it tool, CogState, and pencil‐and‐paper tests) on four
occasions: three times during the first visit and once during the second
visit (see Figure 1 for details of study flow).
FIGURE 1 Flow chart of the study design
TABLE 1 THINC‐it tasks and details of primary metrics for each test
THINC‐it test Comparison test Measure
Spotter Identification Mean latency for correct responses as expressed in msec.a
Symbol Check One‐Back Test Number of correct responses
Codebreaker DSSTb Number of correct responses
Trails Trail Making Test Part B Time taken for completion
aResponses quicker than 100 ms were treated as anticipations.
bDigit Symbol Substitution Test.
TABLE 2 Demographic details of study cohort
Characteristic Results
Age, years (mean [SD]) 39.98 (14.38)
Gender, n (%)
Female 58 (58.00)
Male 42 (42.00)
Ethnicity, n (%)
Caucasian 56 (56.00)
Black 9 (9.00)
Hawaiian 1 (1.00)
Asian 31 (31.00)
Native American 0 (0.00)
South Asian 3 (3.00)
Education, years (from Grade 1; mean [SD]) 16.26 (2.73)
MADRSa score (mean [SD]) 0.77 (1.42)
NART‐Rb full‐scale IQ 111.87 (6.63)
aMontgomery‐Åsberg Depression Rating Scale.
bNational Adult Reading Test (revised).
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The demographics and clinical characteristics of our study participants
are presented inTable 2. The mean age of the 58 females and 42 male
subjects was 40 (SD = 14.4). The group was relatively well educated
and exhibited a National Adult Reading Test—Revised IQ estimate
equal to a full‐scale IQ of 111.87 (SD = 6.63). Data for n = 8 healthy
controls were excluded for those that did not complete the THINC‐it
assessment in its entirety. The primary reasons were the subject's
inability or unwillingness to complete the tasks.
Median and mean values for all THINC‐it and comparison tasks
were found to be similar and so we report only means and confidence
intervals (CI) based on standard errors of the mean. As the data met
the requirements for parametric analysis, we calculated Pearson's “r”
correlations in all cases. These values are reported for each THINC‐it
test measure and as a composite of all four tests, by Visit and Assess-
ment, in Table 3, together with the same statistics for all four paper‐
and‐pencil versions of the selected paradigms, as well as for a compos-
ite score of all four THINC‐it tasks.
Temporal, or “test–retest,” reliability was calculated by correlating
Visit 1 Assessment 1 scores with Visit 2 scores, which were separated
for 1 week. This analysis yielded Pearson's “r” correlations for the fourobjective measures varying between 0.74 and 0.81 (all significant at
<0.001) and a value of 0.72 for the PDQ‐D‐5 (seeTable 4). These cor-
relations were higher when comparisons were made between Visit 1
TABLE 3 Mean and 95% CI (based on standard error of the mean) for objectiveTHINC‐it cognitive measures and their near equivalents by Visit
(V) and Assessment (A)
Test
Visit1 (V1)
Assessment 1 (A1) V1_A2 V1_A3 V2 IRRa (95% CI)
Spotter (mean latency for correct responses) 655 (616–693) 595 (562–629) 569 (539–599) 577 (545–609) 0.93 [0.90, 0.95]
Symbol Check (number correct) 21 (19–23) 27 (24–29) 28 (26–31) 29 (27–31) 0.91 [0.87, 0.94]
Codebreaker (number of correct responses) 55 (51–58) 65 (62–68) 69 (66–73) 69 (65–73) 0.79 [0.7, 0.85]
Trails (time taken for completion) 42 (35–48) 27 (24–31) 27 (21–32) 27 (23–32) 0.70 [0.58, .79]
Mean of all THINC‐it tasks 0.46 (0.45–0.47) 0.49 (0.48–0.50) 0.5 (.49–0.51) 0.5 (0.49–0.51) 0.94 [0.91, 0.96]
Identification (mean latency in ms log10) 2.77 (2.75–2.8) 2.8 (2.75–2.85) 2.77 (2.75–2.79) 2.76 (2.74–2.78) N/A
One‐Back Task (number correct) 28 (26.2–28.8) 29 (27.6–29.7) 29 (27.9–30.1) 29 (27.6–29.8) N/A
DSST (number of correct responses) 62 (59–66) 67 (64–70) 70 (67–74) 72 (68–75) N/A
TMT‐Bb (time taken for completion) 78 (68–89) 64 (58–71) 61 (54–68) 56 (51–61) N/A
aIntrarater reliability (IRR), calculated as the r‐value correlation between V1_A2 and V1_A3.
bTrail Making Test Part B.
TABLE 4 Reliability and stability data for the five THINC‐it test measures (95% CI)
Task (measure) Temporal reliability 1
(V1_A1 to V2)
Temporal reliability 2
(V1_A1 to A2)
Temporal reliability 3
(V1_A3 to V2)
Convergent validity Stability as WSDa
Spotter (mean latency
for correct responses)
0.79 (0.7–0.86) 0.90 (0.85–0.93) 0.86 (0.8–0.9) 0.44 (0.27–0.59) 73.5 (66.3–80.7)
Symbol Check
(number correct)
0.74 (0.64–0.82) 0.68 (0.56–0.78) 0.88 (0.83–0.92) 0.19 (−0.01–0.37) 5.9 (5.3–6.5)
Codebreaker (number
of correct responses)
0.81 (0.73–0.87) 0.84 (0.77–0.89) 0.80 (0.72–0.86) 0.63 (0.49–0.74) 11.23 (10.1–12.3)
Trails (time taken) 0.75 (0.48–1.1) 0.54 (0.38–0.66) 0.82 (0.74–0.88) 0.74 (0.64–0.82) 17.3 (15.6–19.0)
THINC‐it composite 0.91 (0.87–0.94) 0.93 (0.91–0.95) 0.94 (0.91–0.96) 0.42 (0.24–0.58)c 0.81
PDQ‐5‐D (score)b 0.72 (0.6–0.8) 0.72 (0.6–0.8) 0.78 (0.66–0.83) 0.92 (0.88–0.95) 0.76d (0.68–0.83)
aWithin‐subjects standard deviation.
bPerceived Deficits Questionnaire—Depression, 5‐item version for depression.
c(P&P)/0.752 (PDQ‐20).
dFor PDQ “internal consistency.”
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bility, suggesting some repeated exposure effects. We report also the
temporal reliability correlation between Visit 1 Assessments 2 and 3.
Temporal reliability correlations for a THINC‐it composite score are
also reported in Table 4.
Test stability was determined by calculating the WSD value for
each of the THINC‐it measures across Assessments 1 to 3 conducted
at Visit 1. To quantify stability, we calculated the WSD for all four
tests. Test–retest correlations, WSD, and convergent validity for all
five THINC‐it components are reported in Table 4.
Correlation of THINC‐it test performance with comparison tasks
to determine convergent validity yielded correlations between 0.19
for Symbol Check and the OBK test to 0.74 for correlations between
Trails and TMT‐B. Full details of convergent validity correlations with
standard error estimates are shown in Table 4.
The third element of reliability assessed was intrarater reliability.
Empirical research has indicated that benefits of test exposure tend
to accrue between the first two assessments (Falleti, Maruff, Collie,
& Darby, 2006). Based on this assumption, we supposed that much
of the variability attributable to test familiarity, practice, etc. would
be extinguished by the second assessment. We chose therefore to
correlate V1_A2 performance with that collected at V1_A3 to obtainan estimate of intrarater reliability. Levels of intrarater reliability were
observed for all tests to yield values of between 0.7 and 0.93. Specific
values for each test are reported in Table 3. The only THINC‐it task
that lends itself to analysis of internal consistency, the PDQ‐5‐D,
yielded a Cronbach's alpha score of 0.76.4 | DISCUSSION
In this paper, we examined in 100 typical volunteers without a history
of mental disorders, levels of temporal reliability, and test stability of
THINC‐it, a novel screening tool for cognitive impairment in depres-
sion. The assessment of temporal reliability over a 7‐day period (Visits
1 and 2) yielded acceptable to good test–retest reliability correlations
varying between r = 0.74 (Symbol Check) and r = 0.81 (Codebreaker).
Correlations increased to levels of 0.8 and above for all tests when
reliability was calculated between the third assessment of Visits 1
and 2, respectively. This reliability might be indicative of a modest
effect of familiarity with the tests. The reported levels exceed the
threshold for 0.7 specified for acceptable temporal reliability specified
by those working in psychometry (e.g., Kline, 2000, p. 26). The same
threshold of 0.7 is also typically regarded as the minimum acceptable
6 of 8 HARRISON ET AL.level of internal consistency (Kline, 2000, p. 28), which was observed
for the self‐report PDQ‐5‐D questionnaire. The observed Cronbach's
alpha score of 0.76 is also below the level at which tests might be a
“bloated specific,” which can occur when the test items tend to mea-
sure essentially the same construct.
Although the primary ambition of developing THINC‐it is to pro-
vide a cognition screening instrument, we have also sought to imbue
the system with test characteristics that would facilitate the evalua-
tion of cognitive change in group studies, and potentially also in indi-
viduals. Such an approach has been advocated for some time
(Harrison & Maruff, 2008), and emphasis has been placed on the need
for the use of reliable measures (Harrison, 2016). The use of this
methodology relies on the calculation of a Reliable Change Index
(RCI). A variety of methods have been proposed for determining RCI
values, and most methodologies include reliance on measures of tem-
poral reliability (Jacobson & Truax, 1991). The examination of test sta-
bility for the THINC‐it measures, in terms of stability of repeated
measures across very short intervals, in our study in a consecutive
fashion, revealed acceptable levels of temporal reliability that suggest
THINC‐it measures will prove useful measures of cognitive change
using these approaches.
A further method for determining RCI relies on test stability,
whereby Test 1 performance is plotted with a CI, determined using
the WSD. This statistic is calculated using the performance of study
participants on consecutive assessments, such as was conducted in
our study. Later performance can then be compared against the limits
of the Test 1 CI to determine statistically whether the change is a real
change (i.e., outside the CI) or due to chance (i.e., inside the CI).
THINC‐it tests in our validation study yielded relatively low WSD
values. This is a key issue, as if WSD values are too high the resultant
CI can include out of range values. Thus, a lack of reliability places sig-
nificant restrictions on the utility of this approach. The debate about
the utility of different RCI approaches is ongoing (see Hinton‐Bayre,
2011). We will therefore incorporate a variety of methods into
THINC‐it so as to allow users to select their own preferred method
of judging individual patient score change.
Our study also investigated the convergent validity of theTHINC‐
it tests. This was an important aspect of our investigations, as we
wished to determine the extent to which THINC‐it tests performance
converged with other computerized and “paper‐and‐pencil” measures
of the targeted cognitive constructs of attention, working memory,
and executive function. It must be noted that Choice Reaction Time,
the One‐Back Task, and TMT‐B are in no sense what Kline (2000)
titles “benchmark” measures of these cognitive constructs (p. 32). He
proposes that in these circumstances “all that can be expected is a
modest positive correlation of about .3 to .5” (p. 32). Convergent valid-
ity varied between 0.19 and 0.74 for our putative specific measures of
individual cognitive constructs. The level of convergent validity
observed between our general measure, “Codebreaker,” and DSST, a
traditional general test of cognitive function, was 0.63, suggesting that
Codebreaker scores are a reasonable proxy measure of DSST perfor-
mance. Similarly, the correlation of 0.74 between THINC‐it Trails and
TMT‐B indicates that the former is a robust proxy measure of the lat-
ter. However, the convergent validity between the Symbol Check task
and the CogState One‐Back test was considerably lower (r = 0.19).One possible reason for this is the difference in task demands. The
typical One‐Back Task requires a binary “yes” or “no” decision and
response depending on whether the current stimulus is the same as
that presented on the previous trial. Symbol Check requires the study
participant to respond by touching the previous symbol, a choice of
five possibilities. This typically requires the study participants to rap-
idly switch their attention between the stimulus sequence and the
response options. In contrast, the traditional binary decision version
does not typically require visual attention to the possible responses.
It seems likely that Symbol Check taxes attentional and executive
resources to a greater degree than traditional versions of the One‐
Back paradigm. The relative lack of validity suggests that this task is
not a robust proxy measure of the standard One‐Back Task, in our
study exemplified by the CogState version.
A third element of test reliability in our study was our investiga-
tion of intrarater reliability. This analysis yielded reliability scores for
all four tests exceeding the usual minimum acceptable level of 0.7.
Intrarater reliability for the THINC‐it tests varied between a score of
0.7 for the Trails test and a high of 0.93 for the “Spotter” task.
A possible limitation of the study is that the volunteer cohort was
well educated (meanYoE = 16.3, SD = 2.7), with a mean estimated full‐
scale IQ of almost 12‐points above the population mean. Performance
on cognition tests is influenced by both these factors. For example,
Mitrushina et al. (2005, p. 653) suggest a minus 6.45 second subtrac-
tion from standard norm values per extra year of education for every
year over 14 years for theTMT‐B. In our study, the meanTMT‐B score
on first assessment was 78 seconds. The meta‐analysis of TMT‐B per-
formance by age provided by Mitrushina et al. (2005) varies from a
mean score of 54 seconds for 16‐ to 29‐year‐old study participants,
and a score of 105 at the top of our age range. The 40‐ to 44‐year‐old
cohort is the closest to the mean age of our sample (mean age = 40,
SD = 14.38), and for this age group, the reportedmean score is 65 seconds.
This is substantially faster than our group, who at first assessment scored a
mean of 78 seconds. However, it must be recalled that in our study Part A
of theTMTwas not administered. It seems likely that completion of Part A
has a facilitative effect on Part B completion, and this may account for the
observed difference. A further issue to be taken into consideration is that
study participants were recruited using social media. While social media
platforms are commonly utilized by all sections of the general public, it
might be that respondents are among those individuals who are most
comfortable with using digital technology.
In summary, this validation study of THINC‐it has shown the
selected measures to be temporally reliable, to exhibit expected levels
of convergent validity, and high levels of intrarater reliability and test
stability. These observations support the use of THINC‐it as a brief
cognitive testing system with the potential to be employed as a robust
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